U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07156149) titled 'Fabhalta Capsules Specified Drug-use Survey' on Sept. 03.
Brief Summary: The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.
Study Start Date: Sept. 30
Study Type: OBSERVATIONAL
Condition:
C3 Glomerulopathy
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Disclaimer: Curated by HT Syndication....